Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer-Reference-Cited by-同舟云学术

Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer

Published:2020-12-18 Issue:1 Volume:10 Page:27-34
ISSN:2155-6660
Container-title:Journal of Drug Assessment
language:en
Short-container-title:Journal of Drug Assessment

Author:

Husinka Lakyn¹²,Koerner Pamela H.²,Miller Rick T.¹,Trombatt William¹

Affiliation:

1. AllianceRx Walgreens Prime, Pittsburgh, PA, USA

2. Duquesne University School of Pharmacy, Pittsburgh, PA, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/21556660.2020.1857103

Reference20 articles.

1. [ACS] About Breast Cancer. How common is breast cancer? [Internet]. Atlanta (GA): American Cancer Society; 2020 Jan 8 [cited 2020 May 1]; [about 2 screens]. Available from: https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html

2. U.S. Breast Cancer Statistics [Internet]. Ardmore (PA): Breastcancer.org; 2020 Jun 25 [cited 2020 Jul 1]; [about 1 screen]. Available from: https://www.breastcancer.org/symptoms/understand_bc/statistics

3. Overall Mortality After Diagnosis of Breast Cancer in Men vs Women

4. NCCN Clinical Practice Guidelines in Oncology (US). Breast Cancer. Rev. ed. Plymouth Meeting (PA): National Comprehensive Cancer Network (US); 2020.

5. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity;Pharmacogenomics;2024-08-02

2. Adherence to oral anticancer treatments: network and sentiment analysis exploring perceived internal and external determinants in patients with metastatic breast cancer;Supportive Care in Cancer;2024-06-25

3. Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2− Metastatic Breast Cancer;Cancers;2024-06-07

4. Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors;Acta Pharmaceutica;2023-12-01

5. Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer;Patient Preference and Adherence;2023-04